RxDoctor Payments Data

Desirai Rogan, MD

Internal Medicine · Saint Louis, MONPI 1982085759

Payments from drug & device makers

$9,483in general payments, 2019–2025

Across 563 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$943
  • Pfizer$844
  • E.r. Squibb & Sons, L.L.C.$342
  • Novartis$326
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,465100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,483 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$64,729
Medicare patients
276
Services billed
950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$114,651
EliquisApixaban60$84,684
TrulicityDulaglutide50$58,294
FarxigaDapagliflozin Propanediol32$27,481
MyrbetriqMirabegron40$25,472
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$23,510
XareltoRivaroxaban12$17,085
ArexvyRsvpref3 Antigen/As01e/Pf28$6,613
Breo ElliptaFluticasone/Vilanterol18$6,596
Pitavastatin Calcium12$5,793
SynthroidLevothyroxine Sodium62$5,043
Atorvastatin Calcium489$4,047
Levothyroxine Sodium392$4,015
Albuterol Sulfate HfaAlbuterol Sulfate113$3,134
Dexlansoprazole DrDexlansoprazole51$2,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,251$114,65173 claims
PfizerEliquis$844$84,68460 claims
Lilly USA, LLCTrulicity$943$58,29450 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta$225$36,71867 claims
AstraZenecaFarxiga$220$27,48132 claims
Johnson & JohnsonXarelto$209$17,08512 claims
AbbVieSynthroid$2,023$5,04362 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$4,015392 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →